YARAL Pharma is the U.S. generics subsidiary of IBSA, a multinational pharmaceutical company based in Switzerland. Established in 2022, YARAL Pharma is dedicated to providing high-quality, affordable authorized generics and complex generic medicines to the U.S. market. The company aims to improve healthcare outcomes through innovation and exceptional customer service.

YARAL Pharma specializes in authorized generics that are therapeutically equivalent to their branded counterparts. Its product offerings include the Diclofenac Epolamine Topical System 1.3%, Levothyroxine Sodium Capsules, and Lidocaine Patch 5%. The company emphasizes quality assurance and continuity of supply across various therapeutic areas, utilizing advanced manufacturing technologies.

With a commitment to person-centered care, YARAL Pharma serves healthcare providers, pharmacies, and patients by ensuring access to reliable generic medications. The company values quality, innovation, and responsibility, focusing on holistic treatment needs and enhancing patient care in the generics market.